DE69024104D1 - Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase - Google Patents

Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase

Info

Publication number
DE69024104D1
DE69024104D1 DE69024104T DE69024104T DE69024104D1 DE 69024104 D1 DE69024104 D1 DE 69024104D1 DE 69024104 T DE69024104 T DE 69024104T DE 69024104 T DE69024104 T DE 69024104T DE 69024104 D1 DE69024104 D1 DE 69024104D1
Authority
DE
Germany
Prior art keywords
pro
cys
polypeptides
lys
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69024104T
Other languages
English (en)
Other versions
DE69024104T2 (de
Inventor
Enno Prof Christophers
Jens-Michael Dr Schroder
David Dr Pioli
Oliver Dr Wiedow
Michael Derek Dr Edge
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898913349A external-priority patent/GB8913349D0/en
Priority claimed from GB898913346A external-priority patent/GB8913346D0/en
Priority claimed from GB898921613A external-priority patent/GB8921613D0/en
Priority claimed from GB898924717A external-priority patent/GB8924717D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DE69024104D1 publication Critical patent/DE69024104D1/de
Publication of DE69024104T2 publication Critical patent/DE69024104T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69024104T 1989-06-09 1990-06-04 Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase Expired - Lifetime DE69024104T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898913349A GB8913349D0 (en) 1989-06-09 1989-06-09 Polypeptides
GB898913346A GB8913346D0 (en) 1989-06-09 1989-06-09 Polypeptide analogues
GB898921613A GB8921613D0 (en) 1989-09-25 1989-09-25 Polypeptides-1st update
GB898924717A GB8924717D0 (en) 1989-11-02 1989-11-02 Polypeptides

Publications (2)

Publication Number Publication Date
DE69024104D1 true DE69024104D1 (de) 1996-01-25
DE69024104T2 DE69024104T2 (de) 1996-06-13

Family

ID=27450350

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69024104T Expired - Lifetime DE69024104T2 (de) 1989-06-09 1990-06-04 Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase

Country Status (16)

Country Link
US (4) US5464822A (de)
EP (1) EP0402068B1 (de)
JP (1) JP2989853B2 (de)
AT (1) ATE131493T1 (de)
AU (1) AU636148B2 (de)
CA (1) CA2018592C (de)
DE (1) DE69024104T2 (de)
DK (1) DK0402068T3 (de)
ES (1) ES2080800T3 (de)
FI (1) FI106471B (de)
GR (1) GR3018401T3 (de)
IE (1) IE70520B1 (de)
IL (1) IL94602A (de)
NO (1) NO177716C (de)
NZ (1) NZ233974A (de)
PT (1) PT94326B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
IE911697A1 (en) * 1990-05-24 1991-12-04 Zeneca Ltd Therapeutic agent
DE69131058T2 (de) * 1990-05-24 1999-09-09 Zeneca Ltd Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5835061A (en) 1995-06-06 1998-11-10 Wayport, Inc. Method and apparatus for geographic-based communications service
US8606851B2 (en) 1995-06-06 2013-12-10 Wayport, Inc. Method and apparatus for geographic-based communications service
EP0834556A1 (de) * 1996-09-25 1998-04-08 Academisch Ziekenhuis Leiden Verfahren zur Zellkultivierung
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2001241913A1 (en) * 2000-03-01 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for wound treatment
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US20030119073A1 (en) * 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
EP2902501B1 (de) 2002-01-28 2020-04-15 Life Technologies Corporation Herstellung von biologischen, zur Herstellung von cDNS geeigneten Rohextrakten mittels Protease
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
FR2849375B1 (fr) * 2002-12-30 2006-10-20 Jean Noel Thorel Compositions cosmetiques, par exemple pour traiter le vieillissement cutane photo-induit
EP1620121A2 (de) * 2003-05-07 2006-02-01 VIB vzw Verwendung eines polypeptidteil von slpi zur modulierung des tumor- und metastase potentiel der krebszellen
WO2006122404A1 (en) * 2005-05-16 2006-11-23 Her Majesty The Queen In Right As Represented By The Minister Of Health Trappin-2 (elafin) inhibits hiv
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
EP2367954B1 (de) 2008-12-19 2015-02-18 Life Technologies Corporation Proteinase k inhibitore, verfahren und zusammensetzungen davon
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
US20230285523A1 (en) * 2021-12-20 2023-09-14 Tiakis Biotech Ag Use of elafin in the treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
ATE162931T1 (de) * 1989-02-23 1998-02-15 Blood Res Center Menschlicher elastase-inhibitor
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff

Also Published As

Publication number Publication date
PT94326A (pt) 1991-02-08
DE69024104T2 (de) 1996-06-13
AU5680890A (en) 1990-12-13
GR3018401T3 (en) 1996-03-31
IE70520B1 (en) 1996-12-11
FI106471B (fi) 2001-02-15
NZ233974A (en) 1993-05-26
IE902006L (en) 1990-12-09
NO177716C (no) 1995-11-08
NO902444D0 (no) 1990-06-01
IL94602A0 (en) 1991-04-15
JPH03148299A (ja) 1991-06-25
DK0402068T3 (da) 1996-04-22
ATE131493T1 (de) 1995-12-15
ES2080800T3 (es) 1996-02-16
US20020187535A1 (en) 2002-12-12
NO177716B (no) 1995-07-31
US20060068480A1 (en) 2006-03-30
CA2018592A1 (en) 1990-12-09
AU636148B2 (en) 1993-04-22
NO902444L (no) 1990-12-10
PT94326B (pt) 1997-01-31
US5464822A (en) 1995-11-07
EP0402068B1 (de) 1995-12-13
IL94602A (en) 1996-06-18
CA2018592C (en) 2002-08-27
EP0402068A1 (de) 1990-12-12
FI902880A0 (fi) 1990-06-08
JP2989853B2 (ja) 1999-12-13
US6245739B1 (en) 2001-06-12
US6893843B2 (en) 2005-05-17

Similar Documents

Publication Publication Date Title
DE69024104D1 (de) Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase
ATE152172T1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
DE3584579D1 (de) Herstellung von polypeptiden mit human-gammainterferon-aktivitaet.
FI916077A0 (fi) Ej glykosylerade proteiner som aer analoga med humant interleukin 3.
DK0592566T3 (da) IL-6-muteiner med reduceret cysteinantal
DE60228136D1 (de) Cytokin-proteinfamilie
ATE110742T1 (de) Peptid-verbindungen.
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
DE68908958T2 (de) Peptide.
CA2118498A1 (en) A novel anti-neoplastic cytokine
CA2004202A1 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
IL82734A0 (en) Interleukin-2 induced anti-neoplastic peptide and its production
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
JPS6429A (en) Antiviral agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WIEDOW, OLIVER, PROF. DR.MED., 24105 KIEL, DE